Podcast Episodes
Back to Search
ASH 2025: Orca Bio has an April 6th PDUFA date from FDA for its cell therapy product, Orca-T, that aims to solve the problem of treatment-related toxicities that come with stem cell transplants
Co-Founder and CEO Nate Fernhoff walks us through this platform and the clinical data that Orca has previously announced, and new data at ASH. Plus, …
9 months, 1 week ago
ASH 2025: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cell. Plus, the future of dual antigen and in vivo CAR-Ts.
She highlights anito-cell's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T c…
9 months, 1 week ago
ASH 2025: Von Willibrand disease is the most common bleeding disorder, though many people have never heard of it. Star Therapeutics is working on a solution that is already in phase 3
Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator.
9 months, 1 week ago
ASH 2025: Legend Biotech CEO Ying Huang discusses new long-term Carvykti data, looming competition, a CD19+CD20 γδ program, and in vivo CAR-T
He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline program…
9 months, 1 week ago
Two veterans from MPM have launched a new VC firm that will focus on investing in the I&I space - and it will leverage collaborations with disease specific philanthropies
Co-Founders Luke Evnin and Steven St. Peter describe the idea behind the firm, the value in partnering with philanthropies who know these diseases be…
9 months, 1 week ago
Oxford, UK based Accession Therapeutics raised $40M from existing investors today to further develop its precision viral delivered immunotherapies. The first program induces cancer cells to make PD-L1
Founder and CEO Bent Jakobsen describes the science behind the platform, which he believes is unique in that it is delivered systemically, but is des…
9 months, 1 week ago
From London: Cancer Research Horizons takes research from Cancer Research UK (and beyond) and invests in the translational work and companies that turn it into cures
CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty…
9 months, 3 weeks ago
Jefferies London: Ipsen has done a string of deals over recent years, including acquiring ImCheck last month. CEO David Loew says the company has billions in firepower to do more
He also goes over the company's programs in aesthetics, liver disease, and oncology.
9 months, 4 weeks ago
Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml
The data has been accepted for an oral presentation on Monday, December 8 and will be followed by a company webcast with more info.
9 months, 4 weeks ago
Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and walks us through a few of his firm's top positions
He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes.
9 months, 4 weeks ago